The chemokines are a large gene superfamily with critical roles in development and immunity. The chemokine receptor CXCR3 appears to play a major role in the trafficking of activated Th1 lymphocytes. There are at least three major ligands for CXCR3: mig/CXCL9, IP-10/CXCL10 and I-TAC/CXCL11, and of these three ligands, CXCL11 is the least well-characterized. In this study, we have cloned a rat ortholog of CXCL11, evaluated its function, and examined its expression in the Th-1-mediated disease, experimental autoimmune encephalomyelitis (EAE) in the rat. Based on its predicted primary amino-acid sequence, rat I-TAC/CXCL11 was synthesized and shown to induce chemotaxis of activated rat T lymphocytes in vitro and the in vivo migration of T lymphocytes when injected into the skin. I-TAC/CXCL11 expression, as determined by RT-PCR, increased in lymph node and spinal cord tissue collected from rats in which EAE had been actively induced, and in spinal cord tissue from rats in which EAE had been passively induced. The kinetics of expression were similar to that of CXCR3 and IP-10/CXCL10, although expression of both CXCR3 and IP-10/CXCL10 was more intense than that of I-TAC/CXCL11 and increased more rapidly in both lymph nodes and the spinal cord. Only minor levels of expression of the related chemokine mig/CXCL9 were observed. Immunohistochemistry revealed that the major cellular source of I-TAC/CXCL11 in the central nervous system (CNS) during EAE is likely to be the astrocyte. Together, these data indicate that I-TAC/CXCL11 is expressed in the CNS during the clinical phase of EAE. However, the observation that I-TAC/CXCL11 is expressed after receptor expression is detected suggests that it is not essential for the initial migration of CXCR3-bearing cells into the CNS.
Cell migration plays a major role in a wide range of biological functions. One such function includes lymphocyte trafficking, which is critical for protective immunity, but when dysregulated, may also drive autoimmunity. 1 At the molecular level, the process of T-lymphocyte migration into lymph nodes and peripheral tissues follows a multistep extravasation paradigm mediated by several classes of molecules including selectins, integrins, cell adhesion molecules and various members of the chemokine gene superfamily. 2 The chemokines are a family of over 40 (generally) small, secreted proteins that mediate chemotaxis and induce various functional changes in subsets of leukocytes in vitro. [3] [4] [5] They are produced by a wide variety of cells, of both haematopoietic and nonhaematopoietic origin, and have been shown to play a critical role in the migration and activation of leukocytes in vivo. On the basis of a distinctive cysteine-containing amino-acid motif present in the predicted primary amino-acid sequence, the chemokines can be divided into two major subfamilies, C-X-C (a) and C-C (b), and two minor subfamilies, C (g) and C-X 3 -C (d). Members of the C-C subfamily, which presently contains the majority of the known chemokines, all demonstrate juxtaposition of the first pair of cysteines within the cysteine signature, while the C-X-C and C-X 3 -C subfamily members contain one or three intervening amino acids between these two cysteines, respectively. The sole member of the C subfamily is missing the first and third cysteines within the motif. [3] [4] [5] While chemokines play a central role in the regulation of normal immune responses by activating/recruiting leukocytes to specific sites, 4, 6, 7 they have been implicated in a range of pathologies including cancer, allergic and inflammatory disorders as well as in infectious diseases such as AIDS. [8] [9] [10] [11] Since chemokines could be important targets for therapeutic interventions in a range of diseases, and the rat is an important species for evaluating therapeutic potential, it is important to clone and characterize rat chemokines.
Of the CXC chemokines, the non-ELR-containing chemokines I-TAC/CXCL11 (The chemokine nomenclature used in this article adheres to the new nomenclature recently described by Zlotnik and Yoshie. 12 ), 13 IP-10/CXCL10 14 and mig/CXCL9 15 bind to a receptor known as CXCR3, 16 that has been implicated in Th1-dependent inflammation 17, 18 this receptor appears to be expressed at high levels on activated Th1 lymphocytes 19, 20 and CXCR3-expressing T cells have been observed in autoimmune pathologies including arthritis, psoriasis and multiple sclerosis. [21] [22] [23] [24] [25] Evidence documenting the expression patterns of CXCL10 and CXCL9 are abundant in the literature, whereas information regarding CXCL11 expression and function, particularly in vivo, are scarce. However, one of the major common features of expression of these chemokines is their upregulation by IFNg, adding further support for a role in Th-1-dependent inflammation. 13, 26 Owing to the potential importance of understanding the pathobiology of the CXCR3/ligand system, we have cloned the rat ortholog of CXCL11 in order to facilitate the study of its biological function in vivo. To this end, we have characterized the activity of this chemokine and have examined its expression in EAE, a Th1-dependent inflammatory disease of the central nervous system (CNS) in the rat. We now report that increased expression of CXCL11 in vivo occurs in the draining lymph nodes during induction of EAE, and in the spinal cord prior to clinical disease onset but only after the appearance of CXCR3, suggesting that it is not involved in the initial recruitment of activated CXCR3 þ T cells into the CNS.
Materials and methods

Cloning of Rat CXCL11 and CXCR3
Degenerate primers were designed against conserved regions of the amino-acid sequence of human CXCL11. 13 Primers were fully degenerate only through the first five amino acids and were pooled out in order to limit the degeneracy in any given pool to 64-fold. The 5 0 primers were designed against the amino-acid sequence RCLCI, at positions 29-33, and were split into three pools, while the 3 0 primers were designed against the amino-acid sequence CLNPKSK, at positions 74-80, and were also split into three pools. Primers were as follows: Primer pools were mixed in all possible combinations to generate nine sets of primer pairs. Each pair was run with oligo dT-primed first strand cDNA as template. The template cDNA was generated from primary rat astrocyte RNA stimulated for 12 h with TNFa, IFNg and IL-1b. Polymerase chain reaction (PCR) conditions were five cycles of denaturation at 941C for 1 min, annealing at 371C for 2 min and extension at 721C for 2 min followed by 30 more cycles where the annealing temperature was increased to 501C. PCR products were acrylamide gelpurified and subcloned into pCR 2.1 (Invitrogen, Carlsbad, CA, USA) for automated sequence analysis using an Applied Biosystems Sequencer (model 373; Applied Biosystems, Inc. Foster City, CA, USA). Sequences were analysed using the Basic Local Alignment Search Tool (BLAST, National Center for Biotechnology Information, Bethesda, MD, USA 27 ), to identify those related to human CXCL11. Sequences homologous to human CXCL11 obtained from a series of products from independent PCR reactions and independently generated cDNA samples were then compared to obtain a consensus sequence for this region of rat CXCL11.
Sequence information obtained from degenerate PCR described above was used to design the following primers for 5 0 RACE: 5 0 -AATGGCAG CAATCAAGGAAG-3 0 and 5 0 -GAGTAACGGCTGTGA CAAAG-3 0 along with a gene-specific complementary DNA (cDNA) amplification primer: 5 0 -AC CTTTGTCCTTTATGAG-3 0 . The same sequence data were also used to design 3 0 RACE primers: 5 0 -CTTTGTCACAGCCGTTACTC-3 0 and 5 0 -TTGATTG CTATTTTGAC-3 0 . 5 0 RACE products were generated using the 5 0 RACE System for Amplification of cDNA Ends (GIBCO-BRL) according to the manufacturer's instructions. Both oligo dT-and genespecific primers were used to generate cDNA samples from stimulated rat astrocyte RNA for use as templates. 3 0 RACE products were generated using the 3 0 RACE System (Gibco-BRL) again with stimulated rat astrocyte RNA as template. Amplification products were gel-purified and subcloned into pCR 2.1 for automated sequencing as described above. Consensus sequences were determined by comparison of data from several products obtained from several independent reactions from each RACE system. The entire rat CXCL11 coding sequence was then PCR amplified using the following primers: 5 0 -CTGCTCTCTGCGAAGAAA-3 0 and 5 0 -GTCAGCT TCTTGGCACAG-3 0 . The PCR product was ligated directly into pCR2.1 and sequence confirmed as described above.
The predicted mature rat CXCL11 amino-acid sequence was synthesized as previously described. 28 A partial rat CXCR3 cDNA was amplified by degenerate RT-PCR using primers based on published human and mouse CXCR3 Genbank entries (NP_001495 and O88410, respectively). Sequencing of the amplified PCR product revealed that it was highly homologous to both mouse and human CXCR3.
Synthesis of RatCXCL11 and Production of Anti-RatCXCL11 Antibodies
RatCXCL11 was synthesized using automated FMOC-based solid-phase peptide synthesis on an ABI model 431A solid-phase peptide synthesizer (software version Synthassistt 2.0) retrofitted with deprotection monitoring as previously described. 13 Correct electrospray (PE-Sciex API100) masses were obtained for the final products. Rabbit antiratCXCL11 polyclonal antibodies were produced by Cambridge Research Biochemicals (Northwich, UK) and supplied as a protein A-sepharose IgG fraction.
Rats
Female Lewis rats aged 7-14 weeks were used throughout the EAE study. These were bred at the Animal Breeding Establishment of the Australian National University under specific pathogen-free conditions. They were housed in conventional mouse rooms and given food and water ad libitum.
In Vitro Chemotaxis
Spleen and lymph node cells were collected from rats. Cells were suspended in RPMI media supplemented with 10 mM HEPES buffer, 100 U/ml penicillin/streptomycin, 0.1 mM nonessential amino acids, 2 mM L-glutamine, and 0.05 mM 2-mercaptoethanol. All components were obtained from Gibco BRL (Rockville, MD, USA). Cells were incubated in RPMI medium either in the presence of 10 mg/ml of Con A (Sigma) or 2 mg/ml PHA (Lidetechnologies, Grand island, NY, USA) for 4 days, or 400 U/ml IL-2 (BD Biosciences, Bedford, MA, USA) for 6 days. Rat lymphocyte chemotaxis in response to rat and human CXCL11 was measured using a 48-well Boyden chamber (Neuro Probe, Inc., Cabin John, MD, USA) as previously described. 13 In brief, agonists were diluted in RPMI medium containing 0.1% BSA and added to the bottom wells of a 48-well chemotaxis chamber. Cells were resuspended in RPMI/BSA and 10 5 cells were added to the top wells of the chamber. A 5 mm PVP-free filter coated on the bottom with 10 mg/ml of human type IV collagen was used. Chambers were incubated for 60 min in a 5% CO 2 -humidified incubator at 371C. After the incubation period, the filters were stained with DiffQuik and the number of lymphocytes migrating to the lower surface was counted in six randomly chosen high-powered fields.
In Vivo Lymphocyte Migration Assay
Single cell suspensions of Lewis rat splenocytes were cultured with 2 mg/ml concanavalin A (ConA). On day 4, the T lymphoblasts were isolated on a Ficoll density gradient (d ¼ 1.077). Naïve Lewis rats were given 9 Â 10 6 cells intravenously (i.v.), and 30 or 300 ng of synthetic rat CXCL11 in 25 ml, or the equivalent volume of phosphate-buffered saline (PBS), were injected intradermally into discrete sites on the skin on the dorsum of the same rat. After 4 h, the skin around the injection sites was collected and processed for histology.
Induction of Active EAE
Myelin basic protein (MBP) was purified from frozen guinea-pig spinal cord according to the method of Eylar et al. 20 GP-MBP in saline was emulsified in an equal volume of incomplete Freund's adjuvant containing heat-killed Mycobacterium butyricum (4 mg/ml). Rats were anaesthetized with isofluorane prior to immunization with 100 ml of emulsion to each hind footpad. Total dose received for each immunization per rat was 25 mg of GP-MBP and 400 mg M. butyricum.
Passive Transfer of EAE
Single cell suspensions were prepared from spleens of donor rats immunized 10 days previously with 50 mg MBP-CFA as described above. Cells were cultured at 2 Â 10 6 cells/ml in RPMI containing 5% FCS, 5 Â 10 À5 M 2ME, 2 mM L-glutamine, antibiotics and 2 mg/ml ConA. Cultures were maintained at 371C in an atmosphere of 5% CO 2 for 96 h, harvested, washed and viable cells transferred i.v. at a dose of 4 Â 10 7 cells/recipient.
Evaluation of Clinical Signs
Rats were examined on a daily basis beginning from day 8 after immunization and day 3 after passive transfer. Clinical disease severity was assessed and scored as previously described 17 using a scale from 1 to 5 as follows: 0, asymptomatic; 1, flaccid distal half of tail; 2, entire tail flaccid; 3, ataxia, difficulty in righting; 4, hindlimb weakness; 5, hindlimb paralysis.
RT-PCR of Chemokines and Chemokine Receptors
Total RNA from spinal cord tissue collected at different times after injection of either incomplete Freund's adjuvant or complete Freund's adjuvant were purified essentially as previously described. 29, 30 The primer sequences are as follows: ratCXCL11f, gccttggctgtgatattgtg, ratCXCL11r, agt gaggaaagcttgtcctg-gaggctg; ratCXCL10f, ccgcgcctatc gccaatgagctgcgc, ratCXCL10r, cttggggacaccttttagcatc ttttgg; muCXCL9f, gaactcagctctgccatgaa, muCXCL9r, ttgccgagtccggatctagg; CXCR3f, tcatcttcctgtcagccagc, CXCR3r, caccaccaccaccaccacta: b-actinf, gcgac gaggcccaga-gcaagagaggc; b-actinr, gctaggagccaggg cagtaatctcc. The sequence of PCR amplification was one cycle of denaturation at 951C for 2 min, followed by annealing at 561C for 30 s and extension at 721C for 1 min. This cycle was followed by 30 s at 951C, 30 s at 561C, and 1 min at 721C, repeated 33 times. Amplification of all cDNAs was in the linear phase under these conditions. The samples were migrated on a 1% agarose gel, and Southern blots were performed using PCR-amplified cDNA products as probes to reveal the bands of interest.
MBP-Specific T-Cell Lines
MBP-specific T cell lines were established from lymph nodes of Lewis rats immunized 10 days earlier with MBP-CFA. 31 The cells were propagated by successive rounds of 3 days of stimulation with 10 mg/ml of antigen in the presence of mitomycin Ctreated syngeneic splenocytes as a source of APCs. The T lymphoblasts were isolated on a Ficoll density gradient and incubated for 10 days in IL-2-containing medium. The T-cell lines were used after the fourth round of restimulation during the first 5 days of propagation in IL-2-containing medium.
Immunohistochemistry
Serial paraffin sections of lumbar spinal cord of Lewis rats with clinical EAE were subjected to antigen retrieval. Endogenous peroxidase activity and nonspecific antibody binding were reduced by incubation with Peroxide block and Power block (InnoGenex Immunohistochemistry Kit, San Remon, CA, USA). The following antibodies were used: mouse anti-rat ED1-biotin (Serotec, Oxford, England), rabbit anti-glial fibrillary acidic protein (GFAP) (Chemicon International, Temecula, CA, USA) and rabbit anti-rat I-TAC IgG (Cambridge Research Biochemicals, Northwich, UK). The choice of secondary antibodies and the developing procedure were carried out according to the manufacturer's instructions. The sections were counterstained with Mayer's haematoxylin and mounted in SuperMount (Sapphire Bioscience, Australia).
Results
Cloning of the Rat Ortholog of CXCL11
A partial rat CXCL11 cDNA was cloned from an unligated cDNA library prepared from IFNg-, IL-1b-and TNFa-stimulated primary astrocytes, using degenerate oligonucleotides and the PCR. The degenerate oligonucleotides used encompassed conserved regions between the known non-ELR CXC chemokines (see Materials and methods). Sequencing of several PCR clones reveal one with high homology to human CXCL11 (data not shown). This sequence was used to clone the full-length cDNA by 5 0 and 3 0 RACE-PCR. The deduced nucleotide and amino-acid sequences of rat CXCL11 are shown in Figure 1a . In comparison to known non-ELR CXC chemokines, rat CXCL11 is closest to the human and mouse CXCL11, followed by human and mouse CXCL9 and CXCL10 (Figure 1b, c) .
Biological Activity of CXCL11 In Vitro
Rat CXCL11 was chemically synthesized as previously described 28 and tested for activity in vitro. The synthetic protein was found to mobilize intracellular calcium in human CXCR3-expressing cell lines with similar potency to human CXCL11, and to heterologously cross-desensitize the receptor to human CXCL10 (data not shown). In order to evaluate the chemotactic activity of rat CXCL11, rat lymphocytes were isolated from peripheral lymph nodes and spleen and incubated in vitro with either concanavalin A, interleukin 2 or phytohaemagglutinin. The ability of rat CXCL11 to induce chemotaxis of these cells was then investigated using the modified Boyden chamber technique (Figure 2 ). For comparison, human CXCL11 was also used in these experiments. Rat CXCL11 dose-dependently stimulated chemotaxis of all of the preparations of lymphocytes, with maximal chemotaxis being evident at concentrations between 10 and 100 nM. Human CXCL11 was generally more potent.
In Vivo Migration of Activated T-Cells Induced by CXCL11
The ability of synthetic rat CXCL11 to induce migration of T lymphocytes in vivo was investigated. ConA-activated lymphocytes were injected Expression of rat CXCL11 in EAE SR McColl et al intravenously and immediately following this, PBS or rat CXCL11 was injected intradermally into discrete areas on the dorsum of the rat (Figure 3a and b). After 4 h, skin biopsies were collected from the site of injection, sections were prepared and stained with haematoxylin and eosin. Mononuclear cells were conspicuous in the blood vessels, attached to the luminal surface of the endothelial cells, in the perivascular space and in the superficial and deep cutaneous tissue following injection of rat CXCL11. In contrast, few mononuclear cells were observed in the control tissues.
Expression of CXCL11, CXCL10, CXCL9 and CXCR3 in Encephalitogenic T-Cell Lines
The expression of CXCL11 and CXCR3 in Th1 lymphocytes that are specific for MBP and that induce EAE when injected i.v. into naïve recipients was examined. As there is no quantitative ELISA available for rat CXCL11, expression was determined by RT-PCR. None of the T-cell lines tested following antigen restimulation contained detectable levels of CXCL11, however, the cells expressed CXCR3 messenger RNA (mRNA) (Figure 4 ). In addition, these cells did not express detectable levels of CXCL10 or CXCL9. These data illustrate two important points. First, that antigen-specific T lymphocytes are not likely to be a major source of CXCL11, CXCL10 or CXCL9, and second that encephalitogenic T lymphocytes express CXCR3 mRNA.
Expression of mRNA for CXCL11 and Related Molecules During Active EAE Rats were immunized to induce EAE and monitored for induction of disease. For comparison with Figure 2 Chemotaxis of rat T lymphocytes in response to CXCL11. T lymphocytes were isolated from the lymph nodes and spleens and cultured in the presence of either ConA, IL-2 or PHA. The cells were then subjected to modified Boyden chamber chemotaxis assays as described in Material and methods. Data are expressed as mean7s.d. of at least n ¼ 10 values. Figure 3 Migration of ConA-activated T lymphocytes in vivo in response to CXCL11. ConA-activated lymphocytes were injected intravenously followed by PBS (a) or 300 ng rat CXCL11 (b) injected into discrete areas on the dorsum of the rat. After 4 h, skin biopsies were collected from the sites of injection, and sections were prepared and stained with haematoxylin and eosin. Representative of three experiments performed with similar results.
Expression of rat CXCL11 in EAE SR McColl et al
mRNA data, the clinical course of actively induced disease for a representative experiment (n ¼ 12) is shown in Figure 5a . RT-PCRs to amplify rat CXCL11, the related chemokines CXCL10 and CXCL9 and their receptor CXCR3, were performed on cDNA prepared from either the draining lymph nodes (popliteal) or spinal cords collected at various time points postimmunization following whole body perfusion with 50À100 ml cold saline. Immunization with MBP-CFA for active EAE led to an increase in the level of CXCL11 expression in the draining lymph nodes (Figure 5b) . A low level of CXCL11 expression was detected in the draining lymph nodes as early as day 2 postimmunization with MBP-CFA with maximal level being observed on day 12 postimmunization. CXCR3 expression was also detected on day 2 postimmunization with MBP-CFA in lymph node tissue. Expression of CXCL10 and CXCL9 was also observed on day 2 postimmunization with MBP-CFA, with expression of CXCL10 being the strongest and peaking at around day 8 postimmunization. As expected, the increase in the level of expression of these four genes was not specific to MBP, as similar increases were observed in lymph nodes taken from animals that had been immunized with CFA alone (data not shown). þ Th1 T cell lines were established as described in Materials and methods. They were assessed on day 5 of propagation in IL-2-containing medium following restimulation with MBP. Total RNA was isolated and reverse-transcribed. The resultant cDNA was used as a template for PCR using oligonucleotide primers designed to amplify CXCL11, CXCL10, CXCR3 or CXCL9. The data in this figure are representative of three experiments conducted with similar results.
In spinal cord tissue, a weak and variable increase in CXCL11 expression was observed on day 8 postimmunization with MBP-CFA, with maximal levels being observed on day 12 postimmunization (Figure 5c ). Strong expression of CXCR3 was observed in the spinal cord from day 8 postimmunization with MBP-CFA with a further increase over the next two time points. Both CXCL11 and CXCR3 remained prominently expressed at day 20 when all animals had recovered from disease. CXCL10 was more strongly expressed than CXCL11 at day 8 but had decreased significantly by recovery at day 20. CXCL9 expression was only detected at a low level regardless of the time point examined. In contrast to the observations made in the draining lymph nodes, expression of all four genes was dependent on MBP in that expression was not observed in spinal cords taken from animals that had been immunized with PBS-CFA only (Figure 5c ).
To more closely examine the kinetics of early expression of CXCL11, CXCL10 and CXCR3 in spinal cord tissue in rats immunized with MBP-CFA, spinal cord tissues were collected on days 4, 6, 7 and 8 postimmunization, and RT-PCR was conducted. CXCL11 expression was not observed on day 4 or 6 postimmunization, but a low level of expression was observed on day 7, with a further increase being observed on day 8 (Figure 5d ). The expression of both CXCR3 and CXCL10 was first observed on day 6 postimmunization, with further increases observed on days 7 and 8 postimmunization. In contrast, and in keeping with the previous observations (Figure 5b ), no CXCL9 expression was observed on any of these days.
Expression of mRNA for CXCL11 and Related Molecules During Passive EAE
Expression of these four genes was also examined in spinal cord tissue taken from rats into which encephalitogenic T lymphocytes had been transferred. EAE characteristically occurs more quickly in this passive model than in the active disease model studied in the previous group of experiments (Figure 6a ). CXCL11 expression was variably detected only at a very low level on day 2 post-transfer of T lymphocytes, but increased on days 4 and 6 post-transfer (Figure 6b ). CXCR3 expression followed a similar pattern, although expression on day 2 was clearly stronger than that observed for CXCL11 at the same point in time. In contrast to that observed for CXCL11 and similarly to that observed for CXCR3, CXCL10 expression was strong by day 2 post-transfer and continued to increase in intensity up to day 6. As observed with active EAE, CXCL9 expression in the spinal cord was very weak.
Expression of CXCL11 in the Spinal Cord During Active EAE
To determine the distribution of CXCL11 protein and its cellular source in the CNS, immunohistochemistry on serial sections of spinal cords removed from rats on day 12 postimmunization was performed. A representative example is shown in Figure 7 . Typically, a mononuclear cell infiltrate was observed to form a perivascular cuff surrounding blood vessels (Figure 7a ). The area immediately surrounding the blood vessels, including the parenchyma was found to stain positively with antiratCXCL11 antibodies (Figure 7b ). When serial sections were stained with either ED1 to identify mononuclear phagocytes (Figure 7d ) or anti-GFAP to identify astrocytes (Figure 7e ), the pattern of distribution indicated that the CXCL11 distribution closely mirrored that of astrocytes (shown at higher magnification in Figure 7c , f). Figure 6 Expression of CXCL11 mRNA in spinal cord tissues during passive EAE. Encephalitogenic T lymphocytes were transferred into naïve recipients as described in Materials and methods and monitored for clinical signs of EAE (a). At various time points postimmunization, the animals were killed, perfused and the spinal cords collected. Total RNA was purified from the spinal cord collected and reverse-transcribed. The resultant cDNA was used as a template for PCR using oligonucleotide primers designed to amplify CXCL11, CXCL10, CXCR3 or CXCL9 (b). As a control for starting levels of template, b-actin primers were used. The data points in this figure (ie each band) are from individual rats from the same experiment. They are representative of three experiments conducted with similar results.
Discussion
Human CXCL11 was discovered by an EST genomics approach in IFNg-, IL-1b-and TNFa-activated astrocytes. 13 Further studies showed that incubation of primary human astrocytes with a combination of IFNg and IL-1b led to a greater than 400 000-fold increase in the level of expression of CXCL11 mRNA, suggesting an important role for this chemokine in CNS inflammation that is Th1-dependent. 13 However, the function and pattern of expression of this chemokine in vivo is virtually unknown. To examine the expression of CXCL11 in EAE in the rat, a Th1-dependent model of CNS inflammation, we cloned and characterized the rat ortholog of CXCL11.
Our data show that rat CXCL11 shares high homology at the nucleotide and amino-acid levels with human and murine CXCL11 13, 32 at values that are in keeping with homologies reported for other chemokines. Based on its predicted amino-acid sequence, rat CXCL11 was synthesized and shown to activate calcium mobilization in a CXCR3-expressing cell line (data not shown). It also crossdesensitized CXCR3 to another CXCR3 ligand, CXCL10, further evidence for its interaction with CXCR3. In addition, rat CXCL11 potently induced chemotaxis in vitro of rat T lymphocytes that had been cultured in the presence of known T-cell mitogens, including ConA, and migration of ConAactivated T lymphocytes from the peripheral blood into subcutaneous tissue.
To assess expression of the CXCL11 gene during the pathogenesis of EAE, oligonucleotides based on the cloned sequence for rat CXCL11 were designed and used in RT-PCR. In addition, oligonucleotides were designed from a partial rat CXCR3 cDNA clone, and primers were also designed for CXCL10 and CXCL9 based on published sequences, to allow a comparison of the expression of these three CXCR3 ligands. In actively induced disease, an increase in the level of mRNA for all three chemokines and their receptor was detected in the draining lymph nodes as early as day 2 after immunization. However, there were differences in the temporal pattern of expression of the three ligands, as well as in the intensity of the level of mRNA detected-CXCL10 expression was highest and peaked earliest, CXCL9 expression was more intense that CXCL11, but was more stable. Our data contrast somewhat to those of Narumi et al, 33 who showed little or no expression of CXCL11 in the draining lymph nodes in a similar model. However, it is possible that our ability to detect CXCL11 expression is due to the fact that we used rat CXCL11 reagents, whereas in that previous study, a mouse cDNA was used in the Northern analysis of the draining lymph nodes. The expression of CXCL10 and CXCL9 was also more intense in our study; however, this may also be due to the fact that we used a more sensitive RT-PCR/Southern blot technique compared with Northern blot analysis used by Narumi et al. These observed differences may be due to differences in the EAE model employed-in our study, purified guinea-pig MBP Expression of rat CXCL11 in EAE SR McColl et al was used as an encephalitogen rather than the guinea-pig brain homogenate used in the study of Narumi et al, and it has been well established that expression and involvement of chemokines in EAE is dependent on variables such as strain of animal and antigen. 34 In the spinal cord of rats with either actively or passively induced EAE, mRNA for CXCL10 and CXCR3 appeared simultaneously, around days 6 and 2 for active and passive disease, respectively. CXCL11 expression was detected later than CXCL10 expression (around days 7 and 4 for active and passive disease respectively) and CXCL9 expression was either very weak or absent. These data are again in contrast to those of Narumi et al, who showed roughly equivalent expression of CXCL10 and CXCL11 (intensity and temporal pattern) in spinal cord tissue from actively induced EAE, but it must be stated that more time points were investigated in the present study and this allowed us to determine that CXCL10 expression was clearly upregulated earlier than that of CXCL11.
The observation of simultaneous expression of both CXCL10 and CXCR3 in the present study in the spinal cords of both active and passive EAE suggests a causal role for CXCL10 in EAE. In terms of passive EAE, a recent study by Fife et al, 35 in the mouse, demonstrated the appearance of CXCL10 in CNS tissue prior to onset of clinical disease. They also demonstrated the appearance of CXCR3 on inflammatory cells infiltrating the CNS at peak disease and that neutralization of CXCL10 inhibited passive EAE. Our data therefore support the interpretation of Fife et al, 35 that the temporal expression of CXCL10 helps govern the accumulation of activated encephalitogenic T lymphocytes into the CNS. However, the role of CXCL10 in EAE is clearly more complex as administration of neutralizing anti-rat IP-10 (CXCL10) to female lewis rats exacerbated actively induced EAE. 33 Although it is difficult to reconcile these two contrasting observations, it may be related to the quite different dosing regimens used in those two studies.
In our study on MBP-induced EAE in rats, CXCL11 mRNA was expressed at least 24 h after the appearance of its receptor, CXCR3, in the CNS. This strongly suggests that CXCL11 is not essential for the initial recruitment of CXCR3 þ T cells. However, it does not rule out a possible role for CXCL11 in subsequent migration of leukocytes within the parenchyma of the CNS. The migration of neuroantigen-specific T cells with an activated phenotype into the CNS is orchestrated by a range of molecules including adhesion molecules, 36, 37 enzymes 38,39 cytokines 37 and chemokines. 34, 40 These cells accumulate in the perivascular space where they set up the recruitment of nonantigenspecific mononuclear cells via cytokine production. Such cytokines include IFNg that may also induce the production of CXCL11 by astrocytes. 13 This could then enhance migration of autoreactive T cells into the parenchyma where demyelination occurs.
The source of CXCL11 and other CXCR3 ligands in the CNS during the development of EAE is an important issue. These chemokines could be produced by resident cells of the CNS following activation and/or by infiltrating leukocytes including encephalitogenic T lymphocytes. Our data examining expression of CXCL11, CXCL10 and CXCL9 in encephalitogenic T lymphocytes cultured in vitro indicate that these cells are not a significant source of CXCR3 ligands in the CNS. Rather, resident cells are likely to be the most important source of CXCL11 and CXCL10. From previous studies, it appears that astrocytes, endothelial cells, and/or infiltrating macrophages play a prominent role in this regard: human CXCL11 was originally cloned from astrocytes 13 and CXCL11 expression has been observed in cultured microglia 13 and endothelial cells.
41 CXCL10 expression has also been observed in these cell types 22, [41] [42] [43] In addition, cultured human monocytes and murine macrophages have also been shown to express CXCL11 and CXCL10 mRNA, 32, 41 suggesting that macrophages of peripheral blood origin infiltrating the CNS may also contribute to the expression of these chemokines during EAE. However, our observations, using immunohistochemistry suggest that astrocytes and not mononuclear phagocytes or microglia are the major source of CXCL11 during EAE and that CXCL11 expression at the protein level may be limited to astrocytes surrounding microvessels.
The issue of why three ligands exist for CXCR3 is central to our understanding of the biology of the CXCR3/ligand system. While this is not a unique occurrence in the chemokine system (other receptors also bind multiple ligands), 5, 6 it is particularly intriguing in this case when considering that all three ligands are expressed in response to at least one common signal-IFNg. While there is currently no proven theory to explain this apparent redundancy, there are two main plausible explanations. First, it is possible that the three ligands are expressed in temporally and site-specific manners that are sufficiently distinct to prevent redundancy in vivo. This has been shown in subcutaneous tissue. 29, 30 Second, it is possible that the ligands have evolved in such a way that they bind distinctly to CXCR3 in different receptor activation states, again circumventing redundancy. A study examining binding characteristics of CXCL11 and CXCL10 indicates that these chemokines are noncompetitive or allotropic agonists for CXCR3. 44 CXCL10 exhibits a single binding affinity for CXCR3, whereas CXCL11 exhibits multiple binding affinities. The binding of these two ligands to different activation states of the receptor also differs. These data imply that ligand hierarchy exists on cell types that display different receptor conformations rasing the possibility that cells in different states of activation and hence bearing CXCR3 in different conformations, may vary in their sensitivity to the ligands.
In conclusion, we have cloned and characterized a rat ortholog of CXCL11, examined the expression of this gene in EAE in the rat, and compared its expression with that of its receptor, CXCR3, and two other CXCR3 ligands, CXCL10 and CXCL9. Our data clearly show an association between CXCL11 expression and T-lymphocyte-dependent CNS inflammation/pathology and although further studies using either specific neutralizing anti-CXCL11 antibodies, or CXCL11-deficient mice will be required to determine whether CXCL11 plays a causal or regulatory role in the pathogenesis of EAE, the cloning of rat CXCL11 will allow further investigation of both the biological and pathological roles of I-TAC and CXCR3.
